Metavia Inc's Business Segments

The company is a clinical-stage biotechnology firm developing pharmaceuticals for cardiometabolic diseases, primarily metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Its main products include Vanoglipel (DA-1241), a GPR119 agonist targeting MASH and Type 2 Diabetes Mellitus (T2DM), which promotes the release of gut peptides involved in glucose and lipid metabolism and weight loss. Vanoglipel has completed Phase 1 and Phase 2a clinical trials, with positive topline results announced and presentations made at major liver disease conferences. The company plans to finalize the Phase 2a Clinical Study Report in 2026. Another key product, DA-1726, is an oxyntomodulin analog acting as a GLP-1 receptor and glucagon receptor dual agonist for obesity treatment, designed for once-weekly subcutaneous administration. DA-1726 has shown improved weight loss in preclinical models and is currently in Phase 1 clinical trials, with positive safety and efficacy data reported. Further dose escalation and titration studies are planned for 2026. The company also maintains four legacy therapeutic programs—ANA001, NB-01, NB-02, and Gemcabene—targeting viral, neurodegenerative, and cardiometabolic diseases, which are under consideration for out-licensing or divestiture. Its operations focus on research and development, clinical trials, and capital raising, with funding challenges identified as significant risks.